⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HRMY News
Harmony Biosciences Holdings, Inc. Common Stock
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
businesswire.com
HRMY
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
businesswire.com
HRMY
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
businesswire.com
HRMY
Harmony Biosciences to Participate in Upcoming Investor Conferences
businesswire.com
HRMY
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
businesswire.com
HRMY
Harmony Biosciences to Present Rare Epilepsy Data at the 36 th International Epilepsy Congress
businesswire.com
HRMY